Bristol-Myers Squibb Company (BMY)
NYSE: BMY · Real-Time Price · USD
46.35
-0.30 (-0.64%)
At close: Jun 27, 2025, 4:00 PM
46.30
-0.05 (-0.11%)
After-hours: Jun 27, 2025, 7:59 PM EDT
BMY Revenue
Bristol-Myers Squibb Company had revenue of $11.20B in the quarter ending March 31, 2025, a decrease of -5.60%. This brings the company's revenue in the last twelve months to $47.64B, up 4.62% year-over-year. In the year 2024, Bristol-Myers Squibb Company had annual revenue of $48.30B with 7.32% growth.
Revenue (ttm)
$47.64B
Revenue Growth
+4.62%
P/S Ratio
1.97
Revenue / Employee
$1,396,950
Employees
34,100
Market Cap
94.33B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 48.30B | 3.29B | 7.32% |
| Dec 31, 2023 | 45.01B | -1.15B | -2.50% |
| Dec 31, 2022 | 46.16B | -226.00M | -0.49% |
| Dec 31, 2021 | 46.39B | 3.87B | 9.09% |
| Dec 31, 2020 | 42.52B | 16.37B | 62.62% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
BMY News
- 1 day ago - U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb's Cell Therapy Labels - Business Wire
- 4 days ago - Cigna sues Bristol Myers over alleged monopoly for multiple myeloma drug Pomalyst - Reuters
- 4 days ago - 10 'Safer' Dividend Buys Of Barron's Better Bets Than T-Bills For June - Seeking Alpha
- 8 days ago - I'm Buying Dividend Giants At Huge Discounts - Seeking Alpha
- 11 days ago - Bristol Myers Squibb Announces Dividend - Business Wire
- 12 days ago - Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel) - Business Wire
- 16 days ago - Dividend Harvesting Portfolio Week 223: $22,300 Allocated, $2,310.77 In Projected Dividends - Seeking Alpha
- 16 days ago - Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025 - Business Wire